Express Scripts ($ESRX) announced that it will cover Gilead Sciences' (GILD) Harvoni (ledipasvir/sofosbuvir) in its Hepatitis Cure Value Program, with effect from January 1, 2017. The company already has AbbVie's Viekira Pak in its portfolio. Express stated that the company is now in position to offer better pricing for Harvoni, due to the success of the program. The cost of treatment is now expected to decline by roughly 50%.
Express’s National Preferred Formulary offers its services to over 25 million customers across the United States. The company also intends to extend the scope of its Express Scripts Oncology Core Value Program to cover medications in the areas of multiple myeloma, non-small cell lung cancer, prostate cancer and renal cell carcinoma.